SecBot SecBot
8-K ·Filed Jun 4, 2026

COO

COOPER COMPANIES, INC.
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001628280-26-040823
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The litigation resolution removes a significant overhang and allows management to proceed with its strategic review of CooperSurgical, which could unlock value. However, the FY2026 revenue guidance cut (organic growth 3.5%-4.5% vs prior 4.5%-5.5%) signals deceleration. Monitor the strategic review outcome and next quarter's organic growth trajectory for signs of stabilization.

DirectionMixed
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

CooperCompanies reported Q2 2026 record revenue of $1.082B (+8% YoY, +5% organic) and Non-GAAP EPS of $1.21 (+26% YoY), beating consensus. However, GAAP EPS was -$0.40 due to a $271.6M net litigation charge to resolve substantially all claims from a 2023 CooperSurgical fertility media recall. FY2026 revenue guidance was lowered to $4.285-$4.321B (organic growth 3.5%-4.5%), down from prior $4.306-$4.346B, while Non-GAAP EPS guidance of $4.58-$4.66 was reaffirmed. The litigation resolution removes a major overhang but the revenue guidance cut tempers the outlook.

Key Financial Metrics

EPS
$1.21
est $1.10 · +10.0%
Revenue
$1.1B
est $1.1B · +3.0% · +7.9% YoY
Rating
beat
Guidance
$4.285B-$4.321B
lowered
Free Cash Flow
$96.4M
Gross Margin
68%

Key Facts

  • Q2 2026 revenue of $1.082B, up 8% reported and 5% organically YoY
  • Non-GAAP diluted EPS of $1.21, up 26% YoY, beating consensus of $1.10
  • GAAP diluted EPS of $(0.40) vs $0.44 YoY, driven by $271.6M net litigation charge
  • Recorded $324.1M accrued litigation liability, partially offset by $52.5M expected insurance recoveries
  • Settlement agreements cover over 95% of claimants from CooperSurgical fertility media recall
  • FY2026 total revenue guidance lowered to $4.285-$4.321B (organic growth 3.5%-4.5%) from prior $4.306-$4.346B
  • FY2026 Non-GAAP diluted EPS guidance reaffirmed at $4.58-$4.66
  • CooperVision revenue $723.5M (+8% reported, +4% organic); CooperSurgical $358.0M (+8% reported, +6% organic)
  • Operating cash flow $182.8M, FCF $96.4M; repurchased $13.1M in stock during Q2
  • Long-term FCF objective exceeding $2.2B for FY2026-2028 reaffirmed

Financial Impact

$271.6M net pre-tax litigation charge ($324.1M gross liability less $52.5M insurance recoveries) recorded in Q2 2026 SG&A; FY2026 revenue guidance reduced by ~$21M at midpoint

revenueepsoperating incomelitigation liabilityguidance

Risk Factors

  • Lowered FY2026 revenue guidance implies slowing organic growth, particularly in CooperVision Asia Pacific (-6% YoY)
  • Remaining ~5% of claimants not yet settled could lead to additional costs
  • Tariff exposure and FX headwinds continue to pressure margins
  • CooperSurgical strategic review outcome uncertain, could result in divestiture or restructuring

Market Snapshot

Exchange
Nasdaq
Sector
Ophthalmic Goods
Analyst Consensus
54% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-040823
Document: coo-20260604.htm0001628280-26-040823
Document: 0001628280-26-040823-index-headers.html0001628280-26-040823
Document: 0001628280-26-040823-index.html0001628280-26-040823
Document: 0001628280-26-040823.txt0001628280-26-040823
8-K Data (Synthetic)0001628280-26-040823

Track record

10 reports on COO

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +7.83% at T+20 after the Jun 4, 2026 report. 2 of 6 went positive at some point.

Filters
  1. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $59.41 Now $61.88 −4.16% settles Nov 25
  2. Oct 15, 20264w ago Institutional Cluster Bearish 4/10 Entry $57.40 to $62.93 Now $61.88 −7.80% ▼ −9.63% −11.05% vs SPY
  3. Sep 17, 20268w ago Insider Cluster Bullish 4/10 Entry $55.29 to $57.94 Now $61.88 +11.92% ▲ +4.79% +4.59% vs SPY
  4. Sep 15, 20268w ago Insider Cluster Neutral 2/10 Entry $54.61 to $54.88 Now $61.88 +13.31% ▲ +0.49% −1.57% vs SPY
  5. Sep 9, 20269w ago Press Release Mixed 6/10 Entry $54.17 to $54.30 Now $61.88 +14.23% ▲ +0.24% −1.88% vs SPY
  6. Jun 4, 202623w ago 8-K Mixed 6/10 Viewing No price data
  7. Jun 4, 202623w ago Press Release Bullish 6/10 Entry $67.34 to $72.61 Now $61.88 −8.11% ▲ +7.83% +5.96% vs SPY
  8. Mar 5, 202636w ago 8-K Bullish 8/10 Entry $76.36 to $70.15 Now $61.88 −18.97% ▼ −8.13% −6.09% vs SPY
  9. Mar 5, 202636w ago Press Release Bullish 8/10 Entry $76.36 to $70.15 Now $61.88 −18.97% ▼ −8.13% −6.09% vs SPY
  10. Feb 24, 202637w ago DEFA14A Neutral 2/10 Entry $83.38 to $71.35 Now $61.88 −25.79% ▼ −14.43% −9.19% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026